SGHT (Sight Sciences) Probability of Financial Distress (%): 0.07% (As of Jun. 25, 2026)


SGHT Sight Sciences Inc SGHT
72 GF Score
Price $5.52
GF Value $4.49
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences Probability of Financial Distress (%)?

Sight Sciences SGHT +0.33% 72 Probability of Financial Distress (%) is 0.07% as of Jun. 25, 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Sight Sciences's Probability of Financial Distress (%) is 0.07%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Sight Sciences  (NAS:SGHT) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Sight Sciences Probability of Financial Distress (%) Related Terms


SGHT vs QSI, TMCI, SI: Probability of Financial Distress (%) Comparison

For the Medical Devices subindustry, Sight Sciences's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences Probability of Financial Distress (%) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Probability of Financial Distress (%) falls into.


SGHT
72GF Score
Sight Sciences Inc SGHT
Probability of Financial Distress (%) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sight Sciences Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-7.20

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.07%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 0.07% mean?
Sight Sciences (SGHT) has a Probability of Financial Distress (%) of 0.07% as of Jun. 25, 2026.
Is Sight Sciences' Probability of Financial Distress (%) too high?
Sight Sciences' current Probability of Financial Distress (%) is 0.07%. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Probability of Financial Distress (%) compare to QSI and TMCI?
Sight Sciences' Probability of Financial Distress (%) of 0.07% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Medical Devices & Instruments company?
A good Probability of Financial Distress (%) depends on the Medical Devices & Instruments industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. Sight Sciences's current Probability of Financial Distress (%) is 0.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.52 — trading 22.9% above its estimated fair value. The current Probability of Financial Distress (%) is 0.07%. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Probability of Financial Distress (%) is 0.07% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.52 is trading 22.9% above its estimated GF Value™ of $4.49. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • Probability of Financial Distress (%): 0.07%
  • GF Value™: $4.49 vs. price of $5.52 (22.9% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score

Get the complete analysis for SGHT

Probability of Financial Distress (%) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.52
Price
$4.49
GF Value